Red Light Holland and Superstar Wiz Khalifa to Launch Naturally Occurring Psilocybin and Mushrooms Wellness Brand: Mistercap

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland’s MISTERCAP brand of psilocybin-based products.

Read more
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.

Read more
Numinus Pilots Mental Health Program for Corporate Clients in Utah

Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.

Read more
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.

Read more
Numinus completes acquisition of Novamind and announces executive appointments

Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.

Read more
Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.

Read more
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy

Cybin announces publication of EMBARK, a model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing.

Read more
Novamind Reports Fiscal Q3 2022 Financial Results and Operating Highlights

Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.

Read more
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.

Read more
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder

Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

Read more



( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )